NR3C2 and hydrops fetalis: The majority of patients were receiving adequate HF therapy with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-1 receptor (ARB) inhibitors (85.7%), betablockers (BB) (85.7%) and mineralocorticoid receptor antagonists (68.6%), respectively, before initiation of ARNI therapy.